Abstract
For efficient gene delivery, chimeric vectors combining non-viral vectors with viral components have been developed. In particular, increasing attention has been paid to viral fusion activity. HVJ (hemagglutinating virus of Japan; Sendai virus) fuses with the cell membrane at neutral pH, and HN and F, fusion proteins of the virus, contribute to the cell fusion. For fusion-mediated gene transfer, DNA-loaded liposomes were fused with UV-inactivated HVJ to form the fusion liposome, HVJ-liposome. Fusion-mediated delivery protects the molecules incorporated in the liposome from degradation in endosomes and lysosomes before reaching the cytoplasm. Reconstituted pseudovirions of fusion-competent viruses such as HVJ and influenza virus have been also developed by a detergent-lysis and-removal method. A more direct and practical approach is the conversion of fusion-competent virions to non-viral gene delivery particles. Based on this concept, the HVJ envelope vector was developed using inactivated particles of HVJ and has been utilized for gene therapy experiments and functional screening for therapeutic genes. A tissue-targeting HVJ envelope vector was also constructed.
Keywords: liposome, paramyxovirus, Sendai virus, fusion, pseudovirion, gene therapy, chimeric vectors, hemagglutinating virus, DNA-loaded liposomes
Current Gene Therapy
Title: Development of Liposomes and Pseudovirions with Fusion Activity for Efficient Gene Delivery
Volume: 11 Issue: 6
Author(s): Yasufumi Kaneda
Affiliation:
Keywords: liposome, paramyxovirus, Sendai virus, fusion, pseudovirion, gene therapy, chimeric vectors, hemagglutinating virus, DNA-loaded liposomes
Abstract: For efficient gene delivery, chimeric vectors combining non-viral vectors with viral components have been developed. In particular, increasing attention has been paid to viral fusion activity. HVJ (hemagglutinating virus of Japan; Sendai virus) fuses with the cell membrane at neutral pH, and HN and F, fusion proteins of the virus, contribute to the cell fusion. For fusion-mediated gene transfer, DNA-loaded liposomes were fused with UV-inactivated HVJ to form the fusion liposome, HVJ-liposome. Fusion-mediated delivery protects the molecules incorporated in the liposome from degradation in endosomes and lysosomes before reaching the cytoplasm. Reconstituted pseudovirions of fusion-competent viruses such as HVJ and influenza virus have been also developed by a detergent-lysis and-removal method. A more direct and practical approach is the conversion of fusion-competent virions to non-viral gene delivery particles. Based on this concept, the HVJ envelope vector was developed using inactivated particles of HVJ and has been utilized for gene therapy experiments and functional screening for therapeutic genes. A tissue-targeting HVJ envelope vector was also constructed.
Export Options
About this article
Cite this article as:
Kaneda Yasufumi, Development of Liposomes and Pseudovirions with Fusion Activity for Efficient Gene Delivery, Current Gene Therapy 2011; 11 (6) . https://dx.doi.org/10.2174/156652311798192789
DOI https://dx.doi.org/10.2174/156652311798192789 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mutagenic Approaches to Modifying Gap Junction Phenotype
Current Drug Targets 2´,3´-Dialdehyde of ATP, ADP, and Adenosine Inhibit HIV-1 Reverse Transcriptase and HIV-1 Replication
Current HIV Research Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology Anti-miRNA-23a Oligonucleotide Suppresses Glioma Cells Growth by Targeting Apoptotic Protease Activating Factor-1
Current Pharmaceutical Design Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews Mutations in MicroRNA Genes and Their Binding Sites are Infrequently Associated with Human Colorectal Cancer in the Kashmiri Population
MicroRNA Current Status of Magnetite-Based Core@Shell Structures for Diagnosis and Therapy in Oncology Short running title: Biomedical Applications of Magnetite@Shell Structures
Current Pharmaceutical Design Editorial [Hot Topic: Novel Kinase Inhibitors in Cancer Therapy (Guest Editors: Ezra E.W. Cohen and Nikolai G. Rainov)]
Reviews on Recent Clinical Trials Techniques and Methods for In Vivo MRI Monitoring of Exogenous and Endogenous Neural Stem Cell-Mediated Brain Repair
Recent Patents on Regenerative Medicine MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer
Current Molecular Medicine Development of <sup>18</sup>F-Labeled PET Probes for Imaging Cell Proliferation
Current Topics in Medicinal Chemistry Novel and Emerging Drugs for Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine Importance of ABC Transporters in Drug Development
Current Pharmaceutical Design Nucleic Acid Aptamers Against Protein Kinases
Current Medicinal Chemistry Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Structural and Mechanistic Bases of the Anticancer Activity of Natural Aporphinoid Alkaloids
Current Topics in Medicinal Chemistry Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design dUTPase in Human Neoplastic Cells as a Potential Target for Therapeutic Intervention
Current Protein & Peptide Science